GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

SanBio Co 4592.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

830

+4.53%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2026

Revenue

—

FY2017FY2026

Net income

−¥3.84bn

FY2017FY2026

Free cash flow

−¥3.84bn

FY2017FY2026

Shareholders' equity

¥13.60bn

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue—————¥22.9m¥447.2m¥741.6m¥490.5m¥949.5m
Research and development¥2.68bn¥2.36bn¥2.85bn¥6.12bn¥4.96bn¥4.07bn¥4.33bn¥3.72bn¥4.16bn¥2.06bn
Operating income−¥4.12bn−¥3.52bn−¥4.54bn−¥7.90bn−¥6.62bn−¥5.80bn−¥5.49bn−¥3.73bn−¥4.38bn−¥1.93bn
Net income−¥3.84bn−¥2.88bn−¥2.64bn−¥5.56bn−¥4.68bn−¥3.39bn−¥5.16bn−¥2.92bn−¥3.94bn−¥1.84bn
Diluted earnings per share-49.23-40.02-38.53-84.97-78.48-65.37-99.60-56.40-79.23-40.09

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets¥15.62bn¥3.45bn¥5.05bn¥7.05bn¥5.51bn¥13.34bn¥15.61bn¥13.98bn¥5.19bn¥6.29bn
Cash and short-term investments¥15.08bn¥2.92bn¥4.45bn¥6.73bn¥4.56bn¥12.48bn¥13.65bn¥12.45bn¥4.65bn¥5.56bn
Total liabilities¥2.02bn¥1.68bn¥2.25bn¥2.62bn¥3.48bn¥4.99bn¥4.68bn¥5.07bn¥4.34bn¥1.70bn
Debt¥1.24bn¥397.0m¥665.0m¥933.0m¥2.52bn¥4.00bn¥4.00bn¥4.03bn¥2.30bn¥1.30bn
Shareholders' equity¥13.60bn¥1.76bn¥2.79bn¥4.43bn¥2.04bn¥8.35bn¥10.93bn¥8.91bn¥853.3m¥4.59bn
Shares outstanding78m72m69m65m60m52m52m52m50m46m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−¥3.81bn−¥3.62bn−¥4.78bn−¥7.45bn−¥6.57bn−¥5.27bn−¥5.73bn−¥4.03bn−¥1.97bn−¥1.83bn
Capital spending−¥32.8m−¥4.9m−¥11.1m−¥7.9m−¥41.7m−¥96.2m−¥95.7m−¥6.4m−¥32.5m−¥97.4m
Free cash flow−¥3.84bn−¥3.62bn−¥4.79bn−¥7.46bn−¥6.61bn−¥5.37bn−¥5.82bn−¥4.03bn−¥2.00bn−¥1.92bn

Latest quarters

By quarter end

Jul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024
Operating income−¥956.6m−¥953.3m−¥1.12bn−¥785.8m−¥880.8m−¥1.01bn−¥1.03bn−¥911.0m
Net income−¥955.5m−¥836.0m−¥1.13bn−¥716.6m−¥465.8m−¥1.53bn−¥730.5m−¥843.2m
Diluted earnings per share-12.24-10.71-14.46-9.95-6.47-21.26-10.14-12.29
Total assets¥13.65bn¥14.52bn¥15.62bn¥2.41bn¥3.22bn¥4.21bn¥3.45bn¥2.56bn
Cash and short-term investments¥12.75bn¥14.00bn¥15.08bn¥1.91bn¥2.74bn¥3.59bn¥2.92bn¥2.04bn
Debt¥1.13bn¥62.0m¥1.24bn¥196.0m¥1.36bn¥268.0m¥268.0m¥268.0m
Shareholders' equity¥11.72bn¥12.68bn¥13.60bn¥492.2m¥1.29bn¥1.90bn¥1.76bn¥616.7m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-19.5%-6.6%13.9%
Net income-11.6%2.6%14.5%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-17.2-42.2-19.5-8.3-10.0-15.4-13.4-46.7-66.5-52.3
Price to sales——————154.8183.8—101.0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.